- Home
- MRM vs SNTI Comparison
MRM vs SNTI Comparison
Compare MRM & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- SNTI
- Stock Information
- Founded
- MRM 2000
- SNTI 2016
- Country
- MRM Japan
- SNTI United States
- Employees
- MRM N/A
- SNTI 48
- Industry
- MRM Other Consumer Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- SNTI Health Care
- Exchange
- MRM Nasdaq
- SNTI Nasdaq
- Market Cap
- MRM 12.2M
- SNTI 14.1M
- IPO Year
- MRM 2020
- SNTI N/A
- Fundamental
- Price
- MRM $4.00
- SNTI $3.05
- Analyst Decision
- MRM
- SNTI
- Analyst Count
- MRM 0
- SNTI 0
- Target Price
- MRM N/A
- SNTI N/A
- AVG Volume (30 Days)
- MRM 2.1M
- SNTI 25.8K
- Earning Date
- MRM 01-01-0001
- SNTI 11-11-2024
- Dividend Yield
- MRM N/A
- SNTI N/A
- EPS Growth
- MRM N/A
- SNTI N/A
- EPS
- MRM 0.16
- SNTI N/A
- Revenue
- MRM $48,438,179.00
- SNTI $338,000.00
- Revenue This Year
- MRM N/A
- SNTI $254.47
- Revenue Next Year
- MRM N/A
- SNTI $169.66
- P/E Ratio
- MRM $25.43
- SNTI N/A
- Revenue Growth
- MRM N/A
- SNTI N/A
- 52 Week Low
- MRM $2.27
- SNTI $1.52
- 52 Week High
- MRM $8.39
- SNTI $8.48
- Technical
- Relative Strength Index (RSI)
- MRM 49.12
- SNTI 63.22
- Support Level
- MRM $3.50
- SNTI $2.81
- Resistance Level
- MRM $4.14
- SNTI $3.14
- Average True Range (ATR)
- MRM 0.69
- SNTI 0.17
- MACD
- MRM -0.07
- SNTI 0.05
- Stochastic Oscillator
- MRM 7.57
- SNTI 88.73
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.